These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 37490069)
1. Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis. Parkes G; Ungaro RC; Danese S; Abreu MT; Arenson E; Zhou W; Ilo D; Laroux FS; Deng H; Sanchez Gonzalez Y; Peyrin-Biroulet L J Gastroenterol; 2023 Oct; 58(10):990-1002. PubMed ID: 37490069 [TBL] [Abstract][Full Text] [Related]
2. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes. Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827 [TBL] [Abstract][Full Text] [Related]
3. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Li K; Marano C; Zhang H; Yang F; Sandborn WJ; Sands BE; Feagan BG; Rubin DT; Peyrin-Biroulet L; Friedman JR; De Hertogh G Gastroenterology; 2020 Dec; 159(6):2052-2064. PubMed ID: 32853634 [TBL] [Abstract][Full Text] [Related]
4. Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. Narula N; Wong ECL; Colombel JF; Riddell R; Marshall JK; Reinisch W; Dulai PS Clin Gastroenterol Hepatol; 2022 May; 20(5):1095-1104.e9. PubMed ID: 34229037 [TBL] [Abstract][Full Text] [Related]
5. Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO Study. Verstockt B; Pouillon L; Ballaux F; Jorissen C; Hoefkens E; Lembrechts N; Bossuyt P J Crohns Colitis; 2023 Jul; 17(7):1046-1054. PubMed ID: 36708189 [TBL] [Abstract][Full Text] [Related]
6. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Danese S; Vermeire S; Zhou W; Pangan AL; Siffledeen J; Greenbloom S; Hébuterne X; D'Haens G; Nakase H; Panés J; Higgins PDR; Juillerat P; Lindsay JO; Loftus EV; Sandborn WJ; Reinisch W; Chen MH; Sanchez Gonzalez Y; Huang B; Xie W; Liu J; Weinreich MA; Panaccione R Lancet; 2022 Jun; 399(10341):2113-2128. PubMed ID: 35644166 [TBL] [Abstract][Full Text] [Related]
7. Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Jangi S; Yoon H; Dulai PS; Valasek M; Boland BS; Jairath V; Feagan BG; Sandborn WJ; Singh S Aliment Pharmacol Ther; 2020 Sep; 52(6):1008-1016. PubMed ID: 33119168 [TBL] [Abstract][Full Text] [Related]
8. Combined Histological and Endoscopic Endpoints at Post-induction Lack Additional Prognostic Value Compared with Endoscopic Improvement Alone in Ulcerative Colitis: A Post hoc Analysis of the VARSITY study. Wong ECL; Dulai PS; Hasan B; Marshall JK; Reinisch W; Narula N J Crohns Colitis; 2023 Jul; 17(7):1114-1121. PubMed ID: 36821429 [TBL] [Abstract][Full Text] [Related]
9. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220 [TBL] [Abstract][Full Text] [Related]
10. End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis. Wong ECL; Hasan B; Dulai PS; Marshall JK; Reinisch W; Narula N Scand J Gastroenterol; 2023 Jan; 58(1):7-14. PubMed ID: 35909369 [TBL] [Abstract][Full Text] [Related]
11. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ; Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039 [TBL] [Abstract][Full Text] [Related]
12. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes. Pandey A; Achrafie L; Kodjamanova P; Tencer T; Kumar J Curr Med Res Opin; 2022 Sep; 38(9):1531-1541. PubMed ID: 35608153 [TBL] [Abstract][Full Text] [Related]
13. Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease. Panés J; Louis E; Bossuyt P; Joshi N; Lee WJ; Lacerda AP; Kligys K; Xuan S; Shukla N; Loftus EV Inflamm Bowel Dis; 2024 Sep; ():. PubMed ID: 39231444 [TBL] [Abstract][Full Text] [Related]
14. Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes. Chen R; Tie Y; Huang Y; Zhang X; Zeng Z; Chen M; Li L; Zhang S United European Gastroenterol J; 2024 May; 12(4):459-468. PubMed ID: 38159047 [TBL] [Abstract][Full Text] [Related]
15. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. Lazzerini M; Villanacci V; Pellegrin MC; Martelossi S; Magazzù G; Pellegrino S; Lucanto MC; Barabino A; Calvi A; Arrigo S; Lionetti P; Fontana M; Zuin G; Maggiore G; Bramuzzo M; Maschio M; Salemme M; Manenti S; Lorenzi L; Decorti G; Montico M; Ventura A Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1382-1389.e1. PubMed ID: 28286192 [TBL] [Abstract][Full Text] [Related]
16. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. Fernández-Blanco JI; Fernández-Díaz G; Cara C; Vera MI; Olivares D; Taxonera C Dig Dis Sci; 2018 Mar; 63(3):731-737. PubMed ID: 29372480 [TBL] [Abstract][Full Text] [Related]
17. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Ikeya K; Sugimoto K; Kawasaki S; Iida T; Maruyama Y; Watanabe F; Hanai H Dig Liver Dis; 2015 May; 47(5):365-71. PubMed ID: 25682993 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1). Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169 [TBL] [Abstract][Full Text] [Related]
19. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Rubin DT; Dotan I; DuVall A; Bouhnik Y; Radford-Smith G; Higgins PDR; Mishkin DS; Arrisi P; Scalori A; Oh YS; Tole S; Chai A; Chamberlain-James K; Lacey S; McBride J; Panés J; Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):17-27. PubMed ID: 34798036 [TBL] [Abstract][Full Text] [Related]
20. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]